These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 28624694)

  • 1. Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases.
    Monneur A; Monnier J; Gaudy-Marqueste C; Devillier R; Sabatier R
    Eur J Cancer; 2017 Aug; 81():138-141. PubMed ID: 28624694
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation.
    Kwong YL
    Ann Hematol; 2016 Jun; 95(7):1191-2. PubMed ID: 27021304
    [No Abstract]   [Full Text] [Related]  

  • 3. Alemtuzumab based reduced intensity conditioning allogeneic haematopoietic stem cell transplantation for myelofibrosis.
    Nagi W; Lim ZY; Krishnamurthy P; Potter V; Tindell V; Reiff-Zall L; Abdullah A; Lea N; Kenyon M; Marsh J; Ho AY; Mufti GJ; Pagliuca A
    Leuk Res; 2011 Aug; 35(8):998-1000. PubMed ID: 21704371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.
    Ljungman P; Bregni M; Brune M; Cornelissen J; de Witte T; Dini G; Einsele H; Gaspar HB; Gratwohl A; Passweg J; Peters C; Rocha V; Saccardi R; Schouten H; Sureda A; Tichelli A; Velardi A; Niederwieser D;
    Bone Marrow Transplant; 2010 Feb; 45(2):219-34. PubMed ID: 19584824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic hematopoietic stem cell transplantation for solid tumors].
    Kanda Y
    Rinsho Ketsueki; 2004 Mar; 45(3):189-94. PubMed ID: 15103931
    [No Abstract]   [Full Text] [Related]  

  • 6. Intensive Chemotherapy plus Hematopoietic Stem Cell Transplantation in Malignancies. Proceedings of the International Consensus Conference. Lyon, France, June 4-6, 1993.
    Ann Oncol; 1993; 4 Suppl 1():1-90. PubMed ID: 8101724
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M; Inui N; Fujisawa T; Enomoto N; Nakamura Y; Kuroishi S; Yokomura K; Koshimizu N; Sato M; Toyoshima M; Shirai T; Masuda M; Yamada T; Imokawa S; Suda T
    Eur J Cancer; 2016 May; 58():30-7. PubMed ID: 26922170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-myeloablative allogeneic stem cell transplantation in patients with solid tumours and patients with a haematological malignancy.
    Huugen D; Bos GM; Jansen M; Lalisang R; Jansen R; Wagstaff J; Schouten HC
    Neth J Med; 2002 May; 60(4):170-3. PubMed ID: 12164395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.
    Urbano-Ispizua A; Schmitz N; de Witte T; Frassoni F; Rosti G; Schrezenmeier H; Gluckman E; Friedrich W; Cordonnier C; Socie G; Tyndall A; Niethammer D; Ljungman P; Gratwohl A; Apperley J; Niederwieser D; Bacigalupo A;
    Bone Marrow Transplant; 2002 Apr; 29(8):639-46. PubMed ID: 12180107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation.
    Lim Z; Baker B; Zuckerman M; Wade JJ; Ceesay M; Ho AY; Devereux S; Mufti GJ; Pagliuca A
    J Infect; 2007 Feb; 54(2):e83-6. PubMed ID: 16806484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
    Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
    Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose chemotherapy with stem cell rescue for solid tumours.
    Protheroe AS; Johnson PW
    Br J Hosp Med; 1996 Apr 3-16; 55(7):437-41. PubMed ID: 8730570
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe.
    Ljungman P; Urbano-Ispizua A; Cavazzana-Calvo M; Demirer T; Dini G; Einsele H; Gratwohl A; Madrigal A; Niederwieser D; Passweg J; Rocha V; Saccardi R; Schouten H; Schmitz N; Socie G; Sureda A; Apperley J;
    Bone Marrow Transplant; 2006 Mar; 37(5):439-49. PubMed ID: 16444286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 15. Checkpoint blockade immunotherapy for cancer comes of age.
    Brower V
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745014
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hematopoietic stem cell transplantation: is it an immunologic therapy?].
    Olaya Vargas A; Pérez Gonzáles O
    Rev Alerg Mex; 2003; 50(5):192-7. PubMed ID: 14631591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The principles and overview of autologous hematopoietic stem cell transplantation.
    Vaughan W; Seshadri T; Bridges M; Keating A
    Cancer Treat Res; 2009; 144():23-45. PubMed ID: 19779877
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions.
    Ho AY; Devereux S; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2003 Apr; 31(7):551-7. PubMed ID: 12692620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.
    Ugurel S; Kiecker F; Fröhling S; Wetter A; Bankfalvi A; Sucker A; Zimmer L; Livingstone E; Roesch A; Becker JC; Schadendorf D
    Eur J Cancer; 2017 Sep; 83():142-145. PubMed ID: 28735071
    [No Abstract]   [Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
    Bornhäuser M; Illmer T; Oelschlaegel U; Schetelig J; Ordemann R; Schaich M; Hänel M; Schuler U; Thiede C; Kiani A; Platzbecker U; Ehninger G
    Clin Cancer Res; 2008 Sep; 14(17):5585-93. PubMed ID: 18765552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.